ReviewBeilstein journal of organic chemistry2026
Triazole-based hybrid molecules in anticancer drug discovery: structural classes and mechanistic insights, 2014-2025.
Review in Beilstein journal of organic chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triazole-based hybrids have evolved into important pharmacophores in the search for anticancer drugs because of their varied biological profiles and structural adaptability. The versatility of triazole scaffolds in forming hybrid molecules with other compounds such as pyridines, coumarins, chalcones, pyrimidines, indoles, etc., has expanded the range of potential anticancer compounds. This review presents an overview of recent progress in the biological assessment of triazole-based hybrid compounds as potential anticancer agents, focusing on their structure, activity, and mechanisms of action. The findings outlined here underscore the therapeutic potential of triazole hybrids and lay the groundwork for designing future anticancer drug candidates.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.